Jade C Bouwer1, Shereen Govender2, Lesley J Robertson1. 1. Department of Psychiatry, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa. 2. National Department of Health, Pretoria, South Africa.
Abstract
BACKGROUND: Access to essential medicines is an integral part of effective health systems. Analysis of medicine procurement may assist with ensuring sustainable access. AIM: To describe the profile and cost of medicines procured for managing mental, neurological and substance use (MNS) disorders during the 2017-2018 financial year. SETTING: The study was conducted in the public health sector in the Gauteng province, South Africa. METHOD: A secondary analysis of the Gauteng Medical Stores Administration System database was performed. Medicine procurement for managing MNS disorders was analysed descriptively by using the World Health Organization's Anatomical Therapeutic Chemical/Defined Daily Dose (ATC/DDD) methodology. Procurement of each medicine was evaluated in local currency (Rands) and in DDD/1000 population served. The District Health Information System was used to estimate population served. RESULTS: Of the total provincial medicines expenditure in 2017-2018, 3.73% was for MNS disorders, which is similar to the spending on cardiovascular (4%) and respiratory (3%) disorders. Antivirals for systemic use comprised 44% of the total expenditure, followed by vaccines at 13%. Of the medicines for MNS disorders, 32.5% of DDDs procured were for anti-epileptics (ATC N03A) at 47.5% of expenditure; 26.2% of DDDs were for antipsychotics (ATC N05A) at 30.9% of expenditure; and antidepressants accounted for 30.8% of DDDs at 6% of expenditure. CONCLUSION: Less than 4% of provincial medicines expenditure was on medicines for MNS disorders, of which almost 78.4% of expenditure was on anti-epileptics and antipsychotics. With limited financial resources, evaluation of procurement patterns raises awareness of relative costs.
BACKGROUND: Access to essential medicines is an integral part of effective health systems. Analysis of medicine procurement may assist with ensuring sustainable access. AIM: To describe the profile and cost of medicines procured for managing mental, neurological and substance use (MNS) disorders during the 2017-2018 financial year. SETTING: The study was conducted in the public health sector in the Gauteng province, South Africa. METHOD: A secondary analysis of the Gauteng Medical Stores Administration System database was performed. Medicine procurement for managing MNS disorders was analysed descriptively by using the World Health Organization's Anatomical Therapeutic Chemical/Defined Daily Dose (ATC/DDD) methodology. Procurement of each medicine was evaluated in local currency (Rands) and in DDD/1000 population served. The District Health Information System was used to estimate population served. RESULTS: Of the total provincial medicines expenditure in 2017-2018, 3.73% was for MNS disorders, which is similar to the spending on cardiovascular (4%) and respiratory (3%) disorders. Antivirals for systemic use comprised 44% of the total expenditure, followed by vaccines at 13%. Of the medicines for MNS disorders, 32.5% of DDDs procured were for anti-epileptics (ATC N03A) at 47.5% of expenditure; 26.2% of DDDs were for antipsychotics (ATC N05A) at 30.9% of expenditure; and antidepressants accounted for 30.8% of DDDs at 6% of expenditure. CONCLUSION: Less than 4% of provincial medicines expenditure was on medicines for MNS disorders, of which almost 78.4% of expenditure was on anti-epileptics and antipsychotics. With limited financial resources, evaluation of procurement patterns raises awareness of relative costs.
Keywords:
Anatomical Therapeutic and Chemical classification/Defined Daily Doses; essential medicines; prescribing patterns; psychopharmacology; rational use
Authors: J Alonso; M C Angermeyer; S Bernert; R Bruffaerts; T S Brugha; H Bryson; G de Girolamo; R Graaf; K Demyttenaere; I Gasquet; J M Haro; S J Katz; R C Kessler; V Kovess; J P Lépine; J Ormel; G Polidori; L J Russo; G Vilagut; J Almansa; S Arbabzadeh-Bouchez; J Autonell; M Bernal; M A Buist-Bouwman; M Codony; A Domingo-Salvany; M Ferrer; S S Joo; M Martínez-Alonso; H Matschinger; F Mazzi; Z Morgan; P Morosini; C Palacín; B Romera; N Taub; W A M Vollebergh Journal: Acta Psychiatr Scand Suppl Date: 2004
Authors: D R Williams; A Herman; D J Stein; S G Heeringa; P B Jackson; H Moomal; R C Kessler Journal: Psychol Med Date: 2007-10-01 Impact factor: 7.723
Authors: Helen Jack; Ryan G Wagner; Inge Petersen; Rita Thom; Charles R Newton; Alan Stein; Kathleen Kahn; Stephen Tollman; Karen J Hofman Journal: Glob Health Action Date: 2014-05-15 Impact factor: 2.640
Authors: Eric I Benchimol; Liam Smeeth; Astrid Guttmann; Katie Harron; David Moher; Irene Petersen; Henrik T Sørensen; Erik von Elm; Sinéad M Langan Journal: PLoS Med Date: 2015-10-06 Impact factor: 11.069